Related Experiment Video
Updated: Jul 2, 2025

07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
305
Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy
Lokesh K Kadian1,2, Deepika Verma1, Neelam Lohani1
1Dept of Biochemistry, All India Institute of Medical Sciences, New Delhi, 110029, India.
Molecular and Cellular Biochemistry
|February 27, 2024
Summary
Long non-coding RNAs (lncRNAs) are key regulators in cancer, influencing gene expression and immune response. Targeting lncRNAs offers potential for improved cancer immunotherapy by enhancing anti-tumor immunity.
Area of Science:
- Molecular Biology
- Oncology
- Immunology
Background:
- Cancer poses a significant global health challenge, with late diagnosis and poor prognosis contributing to high mortality.
- Long non-coding RNAs (lncRNAs) are increasingly recognized as critical regulators of gene expression in human cancers.
- lncRNAs play dual roles, acting as oncogenes or tumor suppressors, and influencing cancer cell proliferation, migration, and invasion.
Purpose of the Study:
- To comprehensively review the multifaceted roles of lncRNAs in human cancers.
- To explore the potential of lncRNAs as therapeutic targets for cancer immunotherapy.
- To examine lncRNA-mediated regulation of cancer cell proliferation, invasion, and immune evasion.
Main Methods:
- Literature review of current research on lncRNAs in cancer and immunology.
- Analysis of lncRNA mechanisms, including competing endogenous RNA (ceRNA) networks.
- Examination of lncRNA involvement in immune cell function and the tumor microenvironment.
Main Results:
- lncRNAs are involved in cancer cell immune escape and modulate the tumor microenvironment.
- Targeting lncRNAs in cancer or immune cells can potentially enhance anti-tumor immune responses.
- lncRNAs regulate cancer progression through various mechanisms, impacting prognosis.
Conclusions:
- lncRNAs are promising targets for novel cancer immunotherapies.
- Further research is crucial to fully elucidate lncRNA functions in cancer and immunity.
- Understanding lncRNA mechanisms can lead to diverse therapeutic applications in oncology.
Related Concept Videos
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Types of RNA
5.8K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
RNA Performs Diverse...
5.8K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K

